“…Since their underlying biology is different, it is reasonable to assume that each subtype may have its own therapeutic vulnerabilities and that tailored therapy or precision medicine may improve patient outcomes (20,21). In practice, though, today the only subtype with an actionable, class-wide vulnerability is MM with translocation t (11;14), which is sensitive to BCL2 inhibition (20,22,23). Arguably, MM with t (11;14) is also the subtype with the most distinctive biological characteristics, including lymphoplasmacytic morphology, frequent expression of B-cell surface antigens, and a possible origin in bone marrow pro-B cells, as opposed to most other myelomas, which arise from post-germinal center B cells (24)(25)(26).…”